Colorectal Neuroendocrine Carcinoma
NCI Definition: An aggressive, high-grade and poorly differentiated carcinoma with neuroendocrine differentiation that arises from the colon or rectum. The mitotic count is more than 20 per 10 HPF. According to the size of the malignant cells, the prominence of the nucleoli, and the amount of cytoplasm, it is classified either as small or large cell neuroendocrine carcinoma. 
Colorectal neuroendocrine carcinomas most frequently harbor alterations in TP53, APC, KRAS, RB1, and BRAF .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, APC Mutation, and KRAS Mutation are the most common alterations in colorectal neuroendocrine carcinoma .
There are 2 clinical trials for colorectal neuroendocrine carcinoma, of which 2 are open and 0 are completed or closed. Of the trials that contain colorectal neuroendocrine carcinoma as an inclusion criterion, 2 are phase 2 (2 open).
Ipilimumab, lenvatinib, and nivolumab are the most common interventions in colorectal neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.